AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16803917 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 89
Study 12801618 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 268
Study 10875189 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation (PR) treatment for insomnia
Number of subjects: 118
Study 10875189 — intervention group
Group type: COMPARATOR
Intervention: Untreated SWI
Number of subjects: 118
Study 10875189 — intervention group
Group type: COMPARATOR
Intervention: Control group (SNI)
Number of subjects: 118
Study 9663828 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg t.d.s. for 6 months
Number of subjects: 14
Study 8460798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 243
Study 8460798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 3947124 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% minoxidil solution
Number of subjects: 47
Study 30195949 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for conduct disorder (CD)
Number of subjects: 1050
Study 30195949 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for attention-deficit hyperactivity disorder (ADHD)
Number of subjects: 1050
Study 30195949 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 1050
Study 30195949 — intervention group
Group type: EXPERIMENTAL
Intervention: Community disadvantage
Number of subjects: 1050
Study 26851964 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min bout of moderate-intensity exercise
Number of subjects: 30
Study 26851964 — intervention group
Group type: COMPARATOR
Intervention: Passive sitting
Number of subjects: 30
Study 25204509 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 2 μg/kg/min (Group L2)
Number of subjects: 40
Study 25204509 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 5 μg/kg/min (Group L5)
Number of subjects: 40
Study 25204509 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) - saline
Number of subjects: 40
Study 24067398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 150 mg twice daily
Number of subjects: 943
Study 24067398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study 24067398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Number of subjects: 943
Study 21422193 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings (20-30 mmHg)
Number of subjects: 58
Study 21422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 58
Study 21422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy for residual telangiectasia
Number of subjects: 58
Study 18294100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 13
Study 16701199 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lenses (unpolished lathe-cut posterior surface)
Number of subjects: 37
Study 16701199 — intervention group
Group type: COMPARATOR
Intervention: Control lenses (polished lathe-cut posterior surface)
Number of subjects: 37
Study 14552597 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelman Z type multiflex Domi classic AC IOL
Number of subjects: 60
Study 14552597 — intervention group
Group type: COMPARATOR
Intervention: Hanita lens with two eyelets (scleral fixated IOL)
Number of subjects: 60
Study 10917405 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 12
Study 10917405 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 120 mg
Number of subjects: 12
Study 10917405 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 180 mg
Number of subjects: 12
Study 10917405 — intervention group
Group type: COMPARATOR
Intervention: Quinidine single-dose (50 mg)
Number of subjects: 12
Study 10917405 — intervention group
Group type: COMPARATOR
Intervention: Quinidine short-term (50 mg four times a day for 4 days)
Number of subjects: 12
Study 8768938 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 < max <= 5 mg)
Number of subjects: 2
Study 8768938 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (higher than 15 mg)
Number of subjects: 2
Study 8768938 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (higher than 10 mg)
Number of subjects: 2
Study 8768938 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and perphenazine
Number of subjects: 2
Study 1348750 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravenous beta‐adrenergic blocking agent therapy
Number of subjects: 3339
Study 1348750 — intervention group
Group type: COMPARATOR
Intervention: Deferred beta‐blocker therapy
Number of subjects: 3339
Study 2940091 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-adrenoceptor blocker metoprolol (n = 88)
Number of subjects: 168
Study 2940091 — intervention group
Group type: COMPARATOR
Intervention: thiazide diuretic hydrochlorothiazide (n = 80)
Number of subjects: 168
Study 2940091 — intervention group
Group type: EXPERIMENTAL
Intervention: both regimens
Number of subjects: 168
Study 31958417 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin plus standard GVHD prophylaxis
Number of subjects: 203
Study 31958417 — intervention group
Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis alone
Number of subjects: 203
Study 29891218 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention and deworming
Number of subjects: 133
Study 29891218 — intervention group
Group type: COMPARATOR
Intervention: Control group (only deworming)
Number of subjects: 133
Study 29891218 — intervention group
Group type: EXPERIMENTAL
Intervention: Household water stored in covered containers
Number of subjects: 133
Study 27554670 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 mg/day omega-3 fatty acid + alpha-tocopherol placebo
Number of subjects: 120
Study 27554670 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day alpha-tocopherol + omega-3 fatty acids placebo
Number of subjects: 120
Study 27554670 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 mg omega-3 fatty acids/day + 400 IU/day alpha-tocopherol
Number of subjects: 120
Study 27554670 — intervention group
Group type: COMPARATOR
Intervention: omega-3 fatty acids placebo + alpha-tocopherol placebo
Number of subjects: 120
Study 24647296 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (Group A)
Number of subjects: 90
Study 24647296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose (Group B)
Number of subjects: 90
Study 24647296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EMLA cream and oral sucrose (Group C)
Number of subjects: 90
Study 22590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal preparation with povidone-iodine solution
Number of subjects: 670
Study 22590998 — intervention group
Group type: COMPARATOR
Intervention: No vaginal preparation (control)
Number of subjects: 670
Study 20217116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake reduced to approximately 1,500 mg/day
Number of subjects: 136
Study 20217116 — intervention group
Group type: COMPARATOR
Intervention: Habitual sodium intake of approximately 3,000 mg/day
Number of subjects: 136
Study 18555934 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg IV q8h
Number of subjects: 476
Study 18555934 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1 g IV q8h
Number of subjects: 476
Study 19509118 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level cluster-randomized balanced designs
Number of subjects: 0
Study 15004444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) of the Pc 6 acupoint (group 1, n = 10)
Number of subjects: 36
Study 15004444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (APr) of the Pc 6 acupoint (group 2, n = 11)
Number of subjects: 36
Study 15004444 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (group 3, n = 8)
Number of subjects: 36
Study 15004444 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure (group 4, n = 7)
Number of subjects: 36
Study 11571447 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 0
Study 11571447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9776435 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg x kg(‐1)
Number of subjects: 30
Study 9776435 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg x kg(‐1)
Number of subjects: 30
Study 9776435 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 7821474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% pretreatment
Number of subjects: 0
Study 7821474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical diclofenac)
Number of subjects: 0
Study 3139310 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil - nitrous oxide
Number of subjects: 60
Study 3139310 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl - nitrous oxide
Number of subjects: 60
Study 31462310 — intervention group
Group type: EXPERIMENTAL
Intervention: Si-ni-tang (SNT) 150 mL per day for 3 days
Number of subjects: 0
Study 31462310 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 150 mL per day for 3 days
Number of subjects: 0
Study 31462310 — intervention group
Group type: EXPERIMENTAL
Intervention: Si-ni-tang (SNT)
Number of subjects: 0
Study 31462310 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 30002931 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 200
Study 30002931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27312248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pin fixation
Number of subjects: 62
Study 27312248 — intervention group
Group type: COMPARATOR
Intervention: Medial-lateral pin fixation
Number of subjects: 62
Study 27312248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 23656441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (short duration <1 h) delivered in the workplace soon after discharge
Number of subjects: 0
Study 23656441 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21901285 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB (BioEnterics Intragastric Balloon) for 6 months
Number of subjects: 50
Study 21901285 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine (pharmacotherapy) for 1 year
Number of subjects: 50
Study 21901285 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB/lifestyle after BIB removal
Number of subjects: 50
Study 21901285 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB/pharmacotherapy after BIB removal
Number of subjects: 50
Study 21901285 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB/lifestyle or BIB/pharmacotherapy
Number of subjects: 50
Study 21901285 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy group
Number of subjects: 50
Study 19623780 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical products designed to improve skin barrier function, hydration, and skin turnover
Number of subjects: 0
Study 19623780 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical products
Number of subjects: 0
Study 17327325 — intervention group
Group type: EXPERIMENTAL
Intervention: Optima Diab walker (group B)
Number of subjects: 40
Study 17327325 — intervention group
Group type: COMPARATOR
Intervention: Total contact casting (TCC; group A)
Number of subjects: 40
Study 16095643 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ + SP
Number of subjects: 364
Study 16095643 — intervention group
Group type: EXPERIMENTAL
Intervention: MQ + AS
Number of subjects: 364
Study 16095643 — intervention group
Group type: EXPERIMENTAL
Intervention: Coartem (lumefantrine + artemether)
Number of subjects: 364
Study 12142121 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Salb) 400 microg administered via inhalation after intravenous N‐omega‐nitro‐monomethyl‐L‐arginine (L‐NMMA) 3 mg/kg over 5 min
Number of subjects: 33
Study 12142121 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (Salb) 400 microg administered via inhalation after control solution (normal saline)
Number of subjects: 33
Study 12142121 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Salb) after L‐NMMA
Number of subjects: 33
Study 12142121 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 33
Study 12142121 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Salb) in CAD patients
Number of subjects: 33
Study 12142121 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) in CAD patients
Number of subjects: 33
Study 10547221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary ketanserin (1.5 mg in 10 ml normal saline administered over 3 min)
Number of subjects: 44
Study 10547221 — intervention group
Group type: COMPARATOR
Intervention: Normal saline alone (control group)
Number of subjects: 44
Study 7801853 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 104
Study 7801853 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 104
Study 7801853 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 104
Study 8703545 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy with doses ranging from 45 to 50 Gy in the compartmental volume after complete resection, and from 55 to 60 Gy in the tumor bed after marginal or incomplete resection.
Number of subjects: 31
Study 526382 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 preceded by fentanyl 1.25 or 2.5 microgram kg‐1 i.v.
Number of subjects: 104
Study 526382 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 preceded by diazepam 0.0625 or 0.125 mg kg‐1 i.v.
Number of subjects: 104
Study 526382 — intervention group
Group type: COMPARATOR
Intervention: thiopentone preceded by fentanyl 1.25 microgram kg‐1 i.v.
Number of subjects: 104
Study 526382 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 preceded by fentanyl 2.5 microgram kg‐1 i.v.
Number of subjects: 104
Study 30120704 — intervention group
Group type: EXPERIMENTAL
Intervention: Images (perceptual form)
Number of subjects: 0
Study 30120704 — intervention group
Group type: COMPARATOR
Intervention: Audio recording or printed text (perceptual forms)
Number of subjects: 0
Study 27853925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel applications with intensive dental prevention in kindergarten
Number of subjects: 6
Study 27853925 — intervention group
Group type: COMPARATOR
Intervention: Fluoride gel applications without intensive dental prevention in kindergarten
Number of subjects: 6
Study 27853925 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum group prevention (intensive prevention in kindergarten and gel program at school)
Number of subjects: 6
Study 25868203 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (FA) 1 mg x kg(‐1) administered at the end of surgery, n = 20
Number of subjects: 40
Study 25868203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FA administration), n = 20
Number of subjects: 40
Study 25868203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FA and control)
Number of subjects: 40
Study 23601744 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg once daily (QD)
Number of subjects: 80
Study 23601744 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg twice daily (BID)
Number of subjects: 80
Study 23601744 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg BID
Number of subjects: 80
Study 23601744 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg QD
Number of subjects: 80
Study 23601744 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg QD
Number of subjects: 80
Study 23601744 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg BID
Number of subjects: 80
Study 21436467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance at 579 ± 21 W (∼30 s)
Number of subjects: 7
Study 21436467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance at work intensities ranging from 395 to 270 W (2.5‐21 min)
Number of subjects: 7
Study 21436467 — intervention group
Group type: EXPERIMENTAL
Intervention: Net rate of plasma K(+) accumulation during an ∼3‐min bout
Number of subjects: 7
Study 21436467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise of ∼1‐4 min
Number of subjects: 7
Study 19873917 — intervention group
Group type: EXPERIMENTAL
Intervention: He's Santong needling methods
Number of subjects: 180
Study 19873917 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Cinnarizine, Cyproheptadine and Vitamin E
Number of subjects: 180
Study 16625520 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental HIV vaccine
Number of subjects: 0
Study 16625520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14988891 — intervention group
Group type: EXPERIMENTAL
Intervention: Left radial approach
Number of subjects: 437
Study 14988891 — intervention group
Group type: COMPARATOR
Intervention: Right radial approach
Number of subjects: 437
Study 14988891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 437
Study 11824022 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pelvic exenteration with sacral resection
Number of subjects: 0
Study 11824022 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative operation
Number of subjects: 0
Study 9741369 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (600 or 800 mg daily)
Number of subjects: 21
Study 9741369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (160 micrograms)
Number of subjects: 21
Study 9741369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline and ipratropium bromide
Number of subjects: 21
Study 9741369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8041232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine HCl (1.25 and 1.9 mg/kg)
Number of subjects: 6
Study 8041232 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.85 g/kg)
Number of subjects: 6
Study 3195055 — intervention group
Group type: EXPERIMENTAL
Intervention: NIVGRIP trivalent inactivated influenza vaccine
Number of subjects: 0
Study 3195055 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 31267222 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 125
Study 31267222 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 125
Study 29390493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ping Chuan Ke Li (PCKL) plus oral montelukast
Number of subjects: 72
Study 29390493 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral montelukast
Number of subjects: 72
Study 26188003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil, 60 mg three times a day for 12 weeks
Number of subjects: 52
Study 26188003 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 52
Study 26188003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 52
Study 26188003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23763983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study 23763983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable consumption intervention
Number of subjects: 0
Study 23763983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (both physical activity and fruit and vegetable consumption)
Number of subjects: 0
Study 23763983 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 0
Study 21768458 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus doxorubicin, cyclophosphamide, and paclitaxel
Number of subjects: 2
Study 21768458 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide followed by paclitaxel
Number of subjects: 2
Study 18807008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 34
Study 18807008 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 34
Study 17096718 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-450 (0.45 g/100 mL)
Number of subjects: 39
Study 17096718 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-350 (0.35 g/100 mL)
Number of subjects: 39
Study 17096718 — intervention group
Group type: COMPARATOR
Intervention: HL-00 (regular formula)
Number of subjects: 39
Study 15543442 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoCITE intervention for 3 hours each weekday for 2 weeks
Number of subjects: 9
Study 15543442 — intervention group
Group type: COMPARATOR
Intervention: Standard Constraint‐Induced Movement therapy (matched group of 12 subjects)
Number of subjects: 9
Study 11340389 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 41
Study 11340389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% brinzolamide
Number of subjects: 41
Study 11340389 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 41
Study 9679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured symptom assessment
Number of subjects: 48
Study 9679262 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study 9679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 48
Study 7974179 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Gy/fraction (group A)
Number of subjects: 165
Study 7974179 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 Gy/fraction (group B)
Number of subjects: 165
Study 2810468 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback training (VFT) group
Number of subjects: 66
Study 2810468 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training (TT) group
Number of subjects: 66
Study 2810468 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 798269 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 100